Cognitive improvement during Tolcapone
treatment in Parkinson's disease

by
Gasparini M, Fabrizio E, Bonifati V, Meco G.
Department of Neurosciences,
University La Sapienza, Rome, Italy.
J Neural Transm. 1997;104(8-9):887-94


ABSTRACT

The aim of this study was to evaluate the effects of Tolcapone, a reversible, selective inhibitor of catechol-O-methyltransferase, on the cognitive function of eight patients with advanced Parkinson's disease. They underwent neuropsychological and motor assessment at baseline and were re-evaluated after 6 months. During this period, they received Tolcapone three times daily, while the L-dopa dosage was progressively reduced. Significant improvements were observed in the attentional task, auditory verbal short-term memory, visuo-spatial recall, constructional praxia and motor symptoms. These data suggest that treatment with Tolcapone, in combination with L-dopa therapy, may determine a significant improvement in cognitive resources of patients with advanced Parkinson's disease.

Tolcapone
Piracetam
Idebenone
Vinpocetine
Vasopressin
Desmopressin
Meclofenoxate
New brain cells
Centrophenoxine
The memory switch?
Dumb-drug euphoria
Growing new brain cells
Piracetam and working memory



Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family